Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan.
Fujimoto S, Koga T, Kawakami A, Kawabata H, Okamoto S, Mizuki M, Yano S, Ide M, Uno K, Yagi K, Kojima T, Mizutani M, Tokumine Y, Nishimoto N, Fujiwara H, Nakatsuka SI, Shiozawa K, Iwaki N, Masaki Y, Yoshizaki K. Fujimoto S, et al. Among authors: shiozawa k. Mod Rheumatol. 2018 Jan;28(1):161-167. doi: 10.1080/14397595.2017.1366093. Epub 2017 Sep 7. Mod Rheumatol. 2018. PMID: 28880697
Prospective study of methotrexate treatment for rheumatoid arthritis treated legitimately according to the government recommended 8 mg/week dose.
Hashiramoto A, Shiozawa K, Tanaka Y, Yamane T, Murata M, Tanaka C, Terashima Y, Koyama K, Nakagawa N, Abe S, Yoshihara R, Saegusa Y, Tsumiyama K, Komai K, Sakai Y, Shiozawa S. Hashiramoto A, et al. Among authors: shiozawa k, shiozawa s. Mod Rheumatol. 2009;19(6):637-42. doi: 10.1007/s10165-009-0205-x. Epub 2009 Jul 22. Mod Rheumatol. 2009. PMID: 19626390
Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients.
Watanabe K, Sakai R, Koike R, Sakai F, Sugiyama H, Tanaka M, Komano Y, Akiyama Y, Mimura T, Kaneko M, Tokuda H, Iso T, Motegi M, Ikeda K, Nakajima H, Taki H, Kubota T, Kodama H, Sugii S, Kuroiwa T, Nawata Y, Shiozawa K, Ogata A, Sawada S, Matsukawa Y, Okazaki T, Mukai M, Iwahashi M, Saito K, Tanaka Y, Nanki T, Miyasaka N, Harigai M. Watanabe K, et al. Among authors: shiozawa k. Mod Rheumatol. 2013 Nov;23(6):1085-93. doi: 10.1007/s10165-012-0796-5. Epub 2012 Dec 5. Mod Rheumatol. 2013. PMID: 23212592
Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial.
Takeuchi T, Tanaka Y, Yamanaka H, Amano K, Nagamine R, Park W, Shiozawa K, Tsukano M, Wei JC, Shao J, Togo O, Mashimo H. Takeuchi T, et al. Among authors: shiozawa k. Mod Rheumatol. 2016;26(1):15-23. doi: 10.3109/14397595.2015.1074648. Epub 2015 Sep 10. Mod Rheumatol. 2016. PMID: 26358841 Clinical Trial.
255 results